

1 **Supplementary table 1. Number of participants with missing data for variables.**

	Metformin users, n=21 n (%)	Non-metformin users, n=120 n (%)	Total, n=141 n (%)
Age at diagnosis	0	4 (3.3)	4 (2.8)
Sex	0	0	0
Method of diagnosis	0	1 (0.8)	1 (0.7)
WHO performance status	4 (19.0)	30 (25.0)	34 (24.1)
AJCC staging	5 (23.8)	29 (24.2)	34 (24.1)
Tumour site in pancreas	0	2 (1.6)	2 (1.4)
Tumour burden	0	4 (3.3)	4 (2.8)
Metastasis site			
<i>Hepatic</i>	1 (4.8)	2 (1.6)	3 (2.1)
<i>Lung</i>	2 (9.5)	3 (2.5)	5 (3.5)
<i>Bone</i>	1 (4.8)	2 (1.6)	3 (2.1)
<i>Abdominal lymph node</i>	1 (4.8)	3 (2.5)	4 (2.8)
<i>Extra-abdominal lymph node</i>	0	4 (3.3)	4 (2.8)
<i>Other</i>	0	4 (3.3)	4 (2.8)
Hepatic metastases			
<i>Number of lesions</i>	2 (9.5)	18 (15.0)	20 (14.2)
<i>Size of largest lesion</i>	6 (28.6)	26 (21.7)	32 (22.7)
Baseline CA19-9	7 (33.3)	39 (32.5)	46 (32.6)
Baseline eGFR	1 (4.8)	0	1 (0.7)
Existing renal disease	1 (4.8)	3 (2.5)	4 (2.8)
Chemotherapy given			
<i>Gemcitabine</i>	0	5 (4.2)	5 (3.5)
<i>FOLFIRINOX</i>	0	5 (4.2)	5 (3.5)
Cigarette smoking status	4 (19.0)	33 (27.5)	37 (26.2)
Outpatient visits	0	6 (5.0)	6 (4.3)
Hospital admissions	0	8 (6.7)	8 (5.7)
Diabetes Mellitus status			
<i>At diagnosis</i>	0	0	0
<i>In follow-up</i>	0	3 (2.5)	3 (2.1)
Nausea and vomiting			
<i>At diagnosis</i>	0	0	0
<i>In follow-up</i>	0	8 (6.7)	8 (5.7)
Duodenal stent in follow-up	0	8 (6.7)	8 (5.7)
Steatorrhoea			
<i>At diagnosis</i>	0	0	0
<i>In follow-up</i>	0	10 (8.3)	10 (7.1)
PPI			
<i>At diagnosis</i>	0	1 (0.8)	1 (0.7)
<i>In follow-up</i>	0	9 (7.5)	9 (6.4)
H2 blocker			
<i>At diagnosis</i>	0	0	0
<i>In follow-up</i>	0	12 (10.0)	12 (8.5)
Pancreatic enzyme supplement			
<i>At diagnosis</i>	0	0	0
<i>In follow-up</i>	0	7 (5.8)	7 (5.0)
Opiates			
<i>At diagnosis</i>	0	3 (2.5)	3 (2.1)
<i>In follow-up</i>	0	7 (5.8)	7 (5.0)

2